Showing 2040 results
-
Story /Novartis has launched a comprehensive research program to help find the right combinations of therapies for the right patients.
-
Featured News /
The Novartis Business Development and Licensing team is behind many of the partnerships that fuel our innovation.
-
Press release /Entresto (sacubitril/valsartan) demonstrated greatest benefit in HFpEF patients with ejection fractions adjacent to HFrEF, compared to valsartan1 Entresto, compared to valsartan, demonstrated…
-
Press release /Sandoz Pharmaceuticals AG wurde offiziell vom Top Employers Institute für ihr hervorragendes Mitarbeiterangebot in der Schweiz ausgezeichnet Die jährliche internationale Forschungstätigkeit des…
-
Press release /Sandoz is the first company to receive approval of a biosimilar in the US through the new FDA biosimilars pathway established under BPCIA Zarxio is approved for all indications included in the…
-
Ad hoc release /Marie-France Tschudin, erfahrene Novartis Führungsperson, zur Präsidentin von Novartis Pharmaceuticals ernannt Basel, 7. Juni 2019 - Novartis kündigte heute an, dass Marie-France Tschudin,…
-
Story / -
In The News /Vas Narasimhan, CEO of Novartis, and CNBC’s Meg Tirrell joins “Closing Bell” in an exclusive interview at the JPMorgan Healthcare Conference.
-
Media Library / -
Press release /Xolair® (omalizumab), indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU)[1], is the only therapy recommended by the guideline for patients unresponsive to…